Tech Company Financing Transactions

IMU Biosciences Funding Round

IMU Biosciences closed a Series A funding round on 6/2/2026. Investors included IQ Capital Fund, Molten Ventures and British Business Bank.

Transaction Overview

Company Name
Announced On
6/2/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Series A
Proceeds Purpose
The company intends to use the funds to support its operational expansion, accelerate the development of its clinical platform infrastructure, and advance its proprietary stem cell and solid organ transplant clinical programs.

Company Information

Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
City Tower, 40 Basinghall Street
London, EC2V 5DE
UK
Phone
Undisclosed
Email Address
Overview
The foundation of IMU is built on the belief that deep systems level immunophenotyping at a population level, powered by the latest advancements in AI and Machine Learning, will lead to a totally new understanding of the immune system and help develop the next-generation precision medicines. IMU is fulfilling this vision with its proprietary discovery engine, and building a comprehensive Immune Atlas that covers the spectrum of health and disease, to advance precision medicine.
Profile
IMU Biosciences LinkedIn Company Profile
Social Media
IMU Biosciences Company Twitter Account
Company News
IMU Biosciences News
Facebook
IMU Biosciences on Facebook
YouTube
IMU Biosciences on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Adam Laing
  Adam Laing LinkedIn Profile  Adam Laing Twitter Account  Adam Laing News  Adam Laing on Facebook
Chief Information Officer
Jeremy Mason
  Jeremy Mason LinkedIn Profile  Jeremy Mason Twitter Account  Jeremy Mason News  Jeremy Mason on Facebook
Chief Operating Officer
Mario Cantero
  Mario Cantero LinkedIn Profile  Mario Cantero Twitter Account  Mario Cantero News  Mario Cantero on Facebook
Chief Scientific Officer
Thomas Hayday
  Thomas Hayday LinkedIn Profile  Thomas Hayday Twitter Account  Thomas Hayday News  Thomas Hayday on Facebook
Chief Technical Officer
Pelle Ullberg
  Pelle Ullberg LinkedIn Profile  Pelle Ullberg Twitter Account  Pelle Ullberg News  Pelle Ullberg on Facebook


 

 

Browse more venture capital transactions:

Prev: 6/2/2026: Recess venture capital transaction
Next: 6/2/2026: NymCard venture capital transaction

 

Share this article

 


News on VC Transactions

We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary